This HTML5 document contains 34 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/drugbank/drug/DB05377/identifier/drugbank/
n6http://bio2rdf.org/drugbank:
n11http://linked.opendata.cz/resource/drugbank/drug/DB05377/identifier/chemspider/
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n10http://linked.opendata.cz/resource/drugbank/drug/DB05377/identifier/pubchem-compound/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB05377
rdf:type
n3:Drug
n3:description
K101 is developed by Moberg Derma for the treatment of onychomycosis (nail fungus) as the primary indication.
n3:group
investigational
n3:indication
Investigated for use/treatment in fungal infections.
owl:sameAs
n6:DB05377
dcterms:title
K101
adms:identifier
n9:DB05377 n10:6635 n11:6383
n3:mechanismOfAction
K101 is a topical solution applied once-daily on affected nails during treatment periods of 3-6 months. In pilot studies, K101 has shown promising results and provides important benefits compared to existing treatment alternatives. There is a significant need for more efficacious topical treatments. For more severe cases of the disease where more than 50% of the nail is affected, the only available options are oral anti-fungals which are associated with a certain risk for severe side effects.
n3:IUPAC-Name
n4:271B41E2-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B41E8-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B41E7-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B41E4-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B41E5-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B41E6-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B41E0-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B41E1-363D-11E5-9242-09173F13E4C5 n4:271B41DE-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B41DF-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B41EE-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B41EF-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B41E9-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B41EA-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B41EC-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B41EB-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B41ED-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B41F2-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B41F4-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B41F5-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B41F1-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B41F0-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B41F3-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B41E3-363D-11E5-9242-09173F13E4C5